Onconano Medicineincis A Clinical Stage Oncology Company Based In Dallastexasthe Company Is Dedicated To Transforming Cancer Therapeutics Through Its Proprietary Nanotechnology Platformonconano Aims To Develop Innovative Treatments That Tackle Significant Challenges In Cancer Care By Utilizing Advanced Technologies For Targeted Therapy Delivery The Company S Core Technology Includes The On Boarda C Polymeric Micelle Platformwhich Allows For Precise Delivery Of Anti Tumor Payloads To The Tumor Microenvironmentonconano Is Advancing A Diverse Pipeline Of Cancer Therapiesincluding Pegsitacianinea Fluorescent Nanoprobe In Phase 2 Clinical Trials For Real Time Surgical Imagingand Onm 501A Next Generation Sting Agonist Moving Towards First In Human Trialsother Preclinical Programssuch As Onm 401Onm 412And Onm 400 Il 2Focus On Various Aspects Of Cancer Treatmentonconano Has Secured Significant Funding To Support Its Research And Development Effortsincluding Approximately $50 Million In Series B Financing In July 2024
No conferences found for this company.
| Company Name | Onconano Medicine Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
